We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: renal cell carcinoma
MedXY News
EnglishTag

renal cell carcinoma

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

AUC3 2025: Expert Consensus Roadmap for Renal Cell and Urinary Tract Cancer Care
newsadjuvant therapyConsensus

AUC3 2025: Expert Consensus Roadmap for Renal Cell and Urinary Tract Cancer Care

By MedXY|Dec 19, 2025

The 2025 Advanced Urologic Cancer Consensus Conference (AUC3) issues practical, evidence‑informed expert recommendations on diagnosis, perioperative therapy, frontline and later‑line systemic sequencing, and special populations for RCC and

Long-Term Efficacy and Safety of Belzutifan in von Hippel-Lindau Disease-Associated Renal Cell Carcinoma: Insights from the 50-Month LITESPARK-004 Phase 2 Study
newsBelzutifanrenal cell carcinoma

Long-Term Efficacy and Safety of Belzutifan in von Hippel-Lindau Disease-Associated Renal Cell Carcinoma: Insights from the 50-Month LITESPARK-004 Phase 2 Study

By MedXY|Oct 24, 2025

Belzutifan demonstrates sustained tumor response and manageable safety over 50 months in patients with von Hippel-Lindau disease-associated renal cell carcinoma, supporting its role as a systemic therapy.

Advancing First-Line Treatment for Advanced Renal Cell Carcinoma: Efficacy of Benmelstobart Plus Anlotinib versus Sunitinib
Nephrologyclinical trialimmunotherapy

Advancing First-Line Treatment for Advanced Renal Cell Carcinoma: Efficacy of Benmelstobart Plus Anlotinib versus Sunitinib

By MedXY|Oct 16, 2025

This phase 3 trial compares benmelstobart plus anlotinib to sunitinib, demonstrating improved progression-free survival and manageable safety in untreated advanced renal cell carcinoma.

Standardizing Pathological Response Reporting After Neoadjuvant Therapy in Kidney Cancer: New International Guidelines
Oncologyguidelinespathology

Standardizing Pathological Response Reporting After Neoadjuvant Therapy in Kidney Cancer: New International Guidelines

By MedXY|Oct 15, 2025

International experts issue consensus guidelines for sampling and reporting pathological response to neoadjuvant therapy in renal cell carcinoma, recommending standardized specimen sampling and quantification of residual viable tumor to ena

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities